[go: up one dir, main page]

US20130303770A1 - Radiolabelled phenylimidazole-based ligands - Google Patents

Radiolabelled phenylimidazole-based ligands Download PDF

Info

Publication number
US20130303770A1
US20130303770A1 US13/890,705 US201113890705A US2013303770A1 US 20130303770 A1 US20130303770 A1 US 20130303770A1 US 201113890705 A US201113890705 A US 201113890705A US 2013303770 A1 US2013303770 A1 US 2013303770A1
Authority
US
United States
Prior art keywords
compound
radioligand
group
methyl
pde10a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US13/890,705
Other versions
US8592449B1 (en
Inventor
Jan Kehler
Benny Bang-Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Priority to US13/890,705 priority Critical patent/US8592449B1/en
Assigned to H. LUNDBECK A/S reassignment H. LUNDBECK A/S ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KEHLER, JAN, BANG-ANDERSEN, BENNY
Publication of US20130303770A1 publication Critical patent/US20130303770A1/en
Application granted granted Critical
Publication of US8592449B1 publication Critical patent/US8592449B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Definitions

  • the present invention relates to compounds suitable for labelling or already labelled with isotopes with short half lives such as 11 C, 15 O, or 18 F, methods of preparing such compounds as well as use of such compounds as a PET ligand for determination of the binding occupancy of a PDE10A enzyme ligand at the PDE10A enzyme or for diagnostic imaging by positron emission tomography (PET).
  • PET positron emission tomography
  • the PDE10A inhibitors can be used to raise levels of cAMP and/or cGMP within cells that express the PDE10A enzyme (or just PDE10A for short), especially neurons that comprise the basal ganglia, and PDE10A inhibitors would therefore be useful in treating a variety of associated neuropsychiatric conditions involving the basal ganglia such as neurological and psychiatric disorders, schizophrenia, bipolar disorder, obsessive compulsive disorder, and the like, and may have the benefit of avoiding side effects, which are associated with the current therapies on the market.
  • WO 08/020302 discloses the use of heteroaromatic quinoline-based compounds that serve as PDE10A inhibitors.
  • WO09/152825 provides phenylimidazole derivative compounds that are PDE10A enzyme inhibitors, and as such are useful to treat neurodegenerative and psychiatric disorders.
  • a difficulty in the development of compounds useful for the treatment of neurological and psychiatric disorders has been the lack of appropriate animal models, the limited accessibility to the brain for pharmacokinetic measurements and lack of adequate direct biomarkers relating to action on the target system. Therefore, more accurate models for performing pharmacokinetic and pharmacodynamic modelling are desired and may be used along with e.g. plasma exposures. It is therefore clear that compounds that may lead to a better pharmacokinetic and pharmacodynamic modelling are valuable.
  • Non-invasive, nuclear imaging techniques can be used to obtain basic and diagnostic information about the physiology and biochemistry of living subjects.
  • isotopes are combined with or chemically reacted with other chemical compounds or pharmaceuticals to form radiolabelled compounds.
  • These compounds once administered to the living subject, can localize to e.g. specific organs, cellular receptors or enzymes. This property of radiopharmaceuticals allows nuclear imaging techniques the ability to produce images which reveal the distribution and concentration of the radiolabelled compound as a function of time.
  • Positron Emission Tomography is of particular interest for drug development because of its high sensitivity and ability to provide quantitative and kinetic data.
  • a short-lived radioactive isotope is injected into the living subject, usually into blood circulation.
  • the radioactive isotope is chemically incorporated into a biologically active molecule, in the case of the present invention the radioactive isotope is incorporated into a PDE10A inhibitor.
  • the radioactive isotope undergoes positron emission decay which eventually leads to the production of annihilation (gamma) photons which are detected when they reach the scintillator in the scanning device.
  • the PET technique therefore depends on radioactive isotopes which undergo positron emission decay.
  • These radioisotopes include carbon-11 (also symbolized 11C or 11 C), nitrogen-13 (also symbolized 13N or 13 N), oxygen-15 (also symbolized 150 or 15 O), and fluorine-18 (also symbolized 18F or 18 F).
  • WO 2006/053785 (Glaxo Group Limited), WO 2006/075226 (Pfizer Products Inc.), WO 2009/033584 (Bayer Schering Pharma AG), and WO 2010/097367 (Janssen Pharmaceutica NV) disclose various radiolabelled compounds for positron emission tomography.
  • the invention provides radiolabelled compounds that bind to PDE10A enzymes and as such are useful in position emission tomography. Accordingly, the present invention relates to a method for determining binding occupancy at the PDE10A enzyme of a PDE10A enzyme ligand by use of a PET ligand of the present invention.
  • the present invention relates to compounds of formula I:
  • the isotopes are selected from the group consisting of 11 C, 15 O, and 18 F;
  • R1-R7 are selected as follows:
  • R1 is a radiolabelled group incorporating or consisting of an isotope selected from 11 C, 15 O, and 18 F, then R2-R7 is selected from H, F, methyl or methoxy;
  • R1 is selected from H; C1-C6 alkyl such as methyl, ethyl, 1-propyl, 2-propyl, isobutyl; C1-C6 alkyl(C3-C8)cycloalkyl such as cyclopropylmethyl; C1-C6 hydroxyalkyl such as hydroxyethyl; flouropropyl; flouroethyl; and flourobutyl.
  • the invention relates to salts or hydrates of the compounds of present invention.
  • the invention relates to methods of production and use of the compounds of the present invention.
  • FIG. 1 shows PET SUV images, summation from 15 to 90 minutes after injection of [11C]Lu AE92686.
  • FIG. 2 shows PET SUV images, 15 to 90 minutes for two monkeys.
  • FIG. 3 shows kinetics of [11C]Lu AE92686 in striatum, results from two monkeys.
  • the X-axis indicates time (minutes), the Y-axis indicates SUV
  • FIG. 4 shows a dose response curve picturing [11C]Lu AE92686 binding to striatum after challenge with three doses of the selective PDE10A inhibitor PF2545920.
  • the X-axis indicates mg/kg of PF2545920, the Y-axis indicates % occupancy.
  • the present invention relates to radiolabelled compounds, their production and the use of said compounds for PET imaging.
  • the first embodiment is denoted E1
  • the second embodiment is denoted E2 and so forth.
  • E6 The compound according to E5 wherein R1 selected from the group consisting of 11 CH 3 , —CH 2 11 CH 3 , — 11 CH 2 CH 3 , —CH 2 CH 2 11 CH 3 , — 11 CH 2 CH 2 CH 3 , — 11 CH 2 CH 2 CH 3 , —CH 2 CH 2 CH 2 11 CH 3 , —CH 2 CH 2 18 F, —CH 2 CH 2 CH 2 18 F, —CH 2 CH 2 CH 2 CH 2 18 F.
  • E17 Use of a compound according to any of E1-E16 as a PET ligand.
  • E18 The use according to E17 for determination of the binding occupancy of a PDE10A enzyme ligand at the PDE10A enzyme.
  • C1-C6 alkyl refers to a straight-chain or branched saturated hydrocarbon having from one to six carbon atoms, inclusive. Examples of such groups include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2-methyl-1-butyl, and n-hexyl.
  • Cl -C6 hydroxyalkyl refers to a C1-C6 alkyl group as defined above which is substituted with one hydroxy group.
  • C 1 -C 6 alkoxy refers to a straight-chain or branched saturated alkoxy group having from one to six carbon atoms, inclusive, with the open valency on the oxygen. Examples of such groups include, but are not limited to, methoxy, ethoxy, n-butoxy, 2-methyl-pentoxy and n-hexyloxy.
  • C3-C8 cycloalkyl typically refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl.
  • C1-C6 alkyl(C3-C8)cycloalkyl refers to a C3-C8 cycloalkyl as defined above which is substituted with a straight-chain or branched C1-C6 alkyl. Examples of such groups include, but are not limited to, cyclopropylmethyl.
  • the present invention also comprises salts of the compounds, typically, pharmaceutically acceptable salts.
  • Such salts include pharmaceutically acceptable acid addition salts.
  • Acid addition salts include salts of inorganic acids as well as organic acids.
  • suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, sulfamic, nitric acids and the like.
  • suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, methanesulfonic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-tol
  • the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like.
  • the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.
  • a radiolabelled compound is a compound comprising one or more isotopes selected from the group consisting of 11 C, 15 O, and 18 F.
  • radiolabelled group is any of R1-R7 comprising at least one isotope selected from the group consisting of 11 C, 18 O, and 18 F.
  • R1-R7 is short notation for the group consisting R1, R2, R3, R4, R5, R6, and R7.
  • R2-R6 means the group consisting R2, R3, R4, R5, and R6.
  • [11C]Lu AE92686 is the radiolabelled compound 5,8-dimethyl-2-[2-([ 11 C-1-methyl]-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyridine
  • PF2545920 is the compound 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline as disclosed in J. Med. Chem., 2009, 52 (16), pp 5188-5196.
  • SUV Standardized uptake value
  • Scheme 1 represents a synthetic route towards compounds of formula I of the invention where R1 is a radiolabelled group. Unless otherwise indicated, in the reaction schemes and discussion that follow, R1-R7, are as defined above.
  • Scheme 2 represents a synthetic route towards compounds of formula I of the invention where R6 is a radiolabelled group.
  • Scheme 3 represents a synthetic route towards compounds of formula I of the invention where R2 is a radiolabelled group.
  • the basic conditions are necessary in order to convert the phosphonium salt 1 into the corresponding Wittig-ylide compound 1A, which is the active nucleofile that condense with the aldehyde compound 2.
  • Different bases can be used and DBU (1,8-Diazabicyclo[5.4.0]undec-7-ene) were found to give the best result.
  • the product of the wittig reaction is the alkene compound 3, which is conveniently isolated in high yield and purity by precipitation from aqueous ethanol and can be used directly without further purification in the next step.
  • the PET-preursor compound II is then formed from the alkene compound 3 by hydrogenation under a hydrogen atmosphere using a hydrogenation catalyst e.g. 5% palladium on charcoal.
  • the syntheses of the PET-preursor compounds of formula Il-V is performed by methods analogues to those described in scheme 5.
  • the starting materials and other reagents are available commercially or can be synthesized by well-known and conventional methods for example as described in WO 2009/152825.
  • a Scanditronix MC17 cyclotron was used to produce 11 C via the 14 N(p,alpha) 11 C nuclear reaction.
  • the target was filled with a mixture of 0.05% oxygen in nitrogen and bombarded with 17 MeV protons to produce [ 11 C]CO 2 .
  • the labeled carbon dioxide was reduced with 0.2 M lithium aluminium hydride in tetrahydrofuran. Treatment with 56% aqueous hydroiodic acid gave [ 11 C]methyl iodide which after drying with phosphorus pentoxide was used for the labeling of the precursor.
  • the precursor (2.5 mg) was dissolved in 300 microL of dry dimethylformamide and approximately 2 mg of crushed sodium hydroxide was added. After thorough shaking, the clear liquid was transferred to another vial. The labeled methyl iodide was introduced and the reaction mixture was heated at 70° C. for 90 seconds. Water (450 microL) was then added and the diluted reaction mixture was injected onto the preparative HPLC column. The collection vial for the product fraction contained 5 mg of ascorbic acid.
  • the solvent of the product fraction collected from the preparative chromatography was removed by means of a rotary evaporator and the residue was redissolved in 5 mL of sterile sodium chloride solution.
  • the formulated tracer was filtered through a 0.2 micro m sterile filter.
  • the product was identified by analytical HPLC using co-injection of the non-radioactive reference compound by comparing the retention times of the UV and radioactive peaks.
  • the total production time including formulation was about 30 minutes.
  • a more rigorous identification of the tracer was done by LC/MS.
  • Active PDE10A enzyme is prepared in a number of ways for use in PDE assays (Loughney, K. et al. Gene 1999, 234, 109-117; Fujishige, K. et al. Eur J Biochem. 1999, 266, 1118-1127 and Soderling, S. et al. Proc. Natl. Acad. Sci. 1999, 96, 7071-7076).
  • PDE10A can be expressed as full-length proteins or as truncated proteins, as long as they express the catalytic domain.
  • PDE10A can be prepared in different cell types, for example insect cells or E. coli .
  • catalytically active PDE10A is as follows: The catalytic domain of human PDE10A (amino acids 440-779 from the sequence with accession number NP 006652) is amplified from total human brain total RNA by standard RT-PCR and is cloned into the BamH1 and Xho1 sites of the pET28a vector (Novagen). Expression in coli is performed according to standard protocols. Briefly, the expression plasmids are transformed into the BL21(DE3) E. coli strain, and 50 mL cultures inoculated with the cells allowed to grow to an OD600 of 0.4-0.6 before protein expression is induced with 0.5 mM IPTG.
  • a PDE10A inhibition assay may for example, be performed as follows: The assay is performed in 60 microL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide substrate), a buffer (50 mM HEPES7.6; 10 mM MgCl 2 ; 0.02% Tween20), 0.1mg/mL BSA, 225 pCi of 3H-labelled cyclic nucleotide substrate, tritium labeled cAMP to a final concentration of 5 nM and varying amounts of inhibitors.
  • Reactions are initiated by addition of the cyclic nucleotide substrate, and reactions are allowed to proceed for one hour at room temperature before being terminated through mixing with 15 uL 8 mg/mL yttrium silicate SPA beads (Amersham). The beads are allowed to settle for one hour in the dark before the plates are counted in a Wallac 1450 Microbeta counter. The measured signal can be converted to activity relative to an uninhibited control (100%) and IC50 values can be calculated using the Xlfit extension to EXCEL.
  • the assay was performed in 60 micro L assay buffer (50 mM HEPES pH 7.6; 10 mM MgCl 2 ; 0.02% Tween20) containing enough PDE10A to convert 20-25% of 10 nM 3 H-cAMP and varying amounts of inhibitors. Following one hour incubation the reactions were terminated by addition of 15 microL 8 mg/mL yttrium silicate SPA beads (Amersham). The beads were allowed to settle for one hour in the dark before the plates were counted in a Wallac 1450 Microbeta counter. IC50 values were calculated by non linear regression using XLfit (IDBS).
  • Lu AE92686 has a very high affinity for the PDE10A enzyme an IC50 value of 0.46 nM. Furthermore, Lu AE92686 is selective for the PDE10A enzyme over other receptors and enzymes screened to date (table 1).
  • the monkey is sedated with ketamin (approximately 10 mg/kg), weighed, and maintained on a constant infusion of ketamin 15 mg/kg/h during transport. During transport the monkey is monitored by pulse oximetry and supported by oxygen. One venous catheter is applied for tracer administration and one venous catheter for blood radioactivity and PK sampling. Propofol is administered until the animal is anesthetized enough to intubate. After intubation the animal is maintained on sevoflurane inhalation anesthesia and artificial ventilation.
  • a 115 microL venous sample is taken at the induction of anesthesia and at the middle and end of experiment for estimation of electrolytes, glucose, hematocrite and glucose.
  • Blood samples (0.2 mL for radioactivity determination are taken at 0.5, 1, 3, 5, 10, 15, 20, 30, 45, 60 and 90 minutes after injection. The samples are labeled with time, date, sampling time in relation to injection, and project number.
  • Blood samples (2 mL) for metabolite analysis are obtained at 5, 30, and 90 minutes after injection of the tracer.
  • Blood sample (1.3 mL) for assessment of free tracer fraction in plasma is taken shortly before each tracer injection.
  • 0.5 mL blood samples are collected 1 minute after the end of each infusion and at 0.5, 15, 30, 60 and 90 minutes after injection of the radiolabelled compound.
  • the samples are collected in tubes containing K 3 EDTA (Microvette 500 K3E, Sarstedt), which are inversed several times to ensure mixing of anticoagulant and blood and stored on ice.
  • the blood samples are centrifuged within 30 minutes and plasma is transferred to a clean polypropylene tube.
  • the samples are stored at ⁇ 80° C.
  • Anaesthesia The monkey is intubated and controlled by respirator at a sevoflurane concentration of about 1.4-4%.
  • Ringer-Acetate (Fresenius-Kabi) 0.5-1 ml/kg/h.
  • Body temperature, heart rate, ECG, pCO 2 , pO 2 , SaO 2 and blood pressure are monitored throughout the PET study.
  • robinyl/neostigmin 2.5 mg is administered when the monkey shows signs of spontaneous breathing.
  • Glucose 300 mg/ml is administered if necessary depending on the blood glucose state as measured.
  • a bolus injection (i.v.) of approximately 5-20 MBq/kg of [ 11 C]Lu AE92686 is used in all studies. PET scanning and arterial blood sampling is commenced upon start of the administration of the radiolabelled compound.
  • Total examination time 90 minutes, 33 frames.
  • the selective PDE10A inhibitor PF2545920 (J. Med. Chem., 2009, 52 (16), pp 5188-5196) was administered intravenously, as an infusion over 15 minutes, starting 30 minutes prior to injection of the [11C]Lu AE92686 radiolabelled compound.
  • PF2545920 was dissolved in 10% HPbetaCD in 0.9% NaCl, pH 4.
  • Three blocking doses of PF2545920 were administered, at concentrations of the drug of 0.11 mg/kg (for the low dose), 0.6 mg/kg (for the middle dose) and 1.5 mg/kg (for the high dose).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention relates to radiolabelled PDE10A ligands which are useful for imaging and quantifying the PDE10A enzyme using positron emission tomography (PET).

Description

    FIELD OF THE INVENTION
  • The present invention relates to compounds suitable for labelling or already labelled with isotopes with short half lives such as 11C, 15O, or 18F, methods of preparing such compounds as well as use of such compounds as a PET ligand for determination of the binding occupancy of a PDE10A enzyme ligand at the PDE10A enzyme or for diagnostic imaging by positron emission tomography (PET).
    • BACKGROUND OF THE INVENTION
  • The PDE10A inhibitors can be used to raise levels of cAMP and/or cGMP within cells that express the PDE10A enzyme (or just PDE10A for short), especially neurons that comprise the basal ganglia, and PDE10A inhibitors would therefore be useful in treating a variety of associated neuropsychiatric conditions involving the basal ganglia such as neurological and psychiatric disorders, schizophrenia, bipolar disorder, obsessive compulsive disorder, and the like, and may have the benefit of avoiding side effects, which are associated with the current therapies on the market.
  • WO 08/020302 (Pfizer Products Incorporated) discloses the use of heteroaromatic quinoline-based compounds that serve as PDE10A inhibitors. WO09/152825 (Lundbeck A/S) provides phenylimidazole derivative compounds that are PDE10A enzyme inhibitors, and as such are useful to treat neurodegenerative and psychiatric disorders.
  • A difficulty in the development of compounds useful for the treatment of neurological and psychiatric disorders has been the lack of appropriate animal models, the limited accessibility to the brain for pharmacokinetic measurements and lack of adequate direct biomarkers relating to action on the target system. Therefore, more accurate models for performing pharmacokinetic and pharmacodynamic modelling are desired and may be used along with e.g. plasma exposures. It is therefore clear that compounds that may lead to a better pharmacokinetic and pharmacodynamic modelling are valuable.
  • Non-invasive, nuclear imaging techniques can be used to obtain basic and diagnostic information about the physiology and biochemistry of living subjects. In nuclear imaging technique procedures, isotopes are combined with or chemically reacted with other chemical compounds or pharmaceuticals to form radiolabelled compounds. These compounds, once administered to the living subject, can localize to e.g. specific organs, cellular receptors or enzymes. This property of radiopharmaceuticals allows nuclear imaging techniques the ability to produce images which reveal the distribution and concentration of the radiolabelled compound as a function of time.
  • Positron Emission Tomography (PET) is of particular interest for drug development because of its high sensitivity and ability to provide quantitative and kinetic data. To conduct a PET scan, a short-lived radioactive isotope is injected into the living subject, usually into blood circulation. The radioactive isotope is chemically incorporated into a biologically active molecule, in the case of the present invention the radioactive isotope is incorporated into a PDE10A inhibitor. The radioactive isotope undergoes positron emission decay which eventually leads to the production of annihilation (gamma) photons which are detected when they reach the scintillator in the scanning device. The PET technique therefore depends on radioactive isotopes which undergo positron emission decay. These radioisotopes include carbon-11 (also symbolized 11C or 11C), nitrogen-13 (also symbolized 13N or 13N), oxygen-15 (also symbolized 150 or 15O), and fluorine-18 (also symbolized 18F or 18F).
  • WO 2006/053785 (Glaxo Group Limited), WO 2006/075226 (Pfizer Products Inc.), WO 2009/033584 (Bayer Schering Pharma AG), and WO 2010/097367 (Janssen Pharmaceutica NV) disclose various radiolabelled compounds for positron emission tomography.
  • Celen et al. Neurolmage 2010, 52, Supplement 1, P. S15, Celen et al. The Journal of Nuclear Medicine 2010; 51: 1584-1591, and Tu et al. Nuclear Medicine and Biology 2010; 37: 509-516 disclose 18F and 11C labelled compounds for PET imaging of PDE10A enzymes in the brain.
    • SUMMARY OF THE INVENTION
  • The invention provides radiolabelled compounds that bind to PDE10A enzymes and as such are useful in position emission tomography. Accordingly, the present invention relates to a method for determining binding occupancy at the PDE10A enzyme of a PDE10A enzyme ligand by use of a PET ligand of the present invention.
  • Accordingly, in one aspect the present invention relates to compounds of formula I:
  • Figure US20130303770A1-20131114-C00001
  • and the use hereof as a PDE10A enzyme ligand in PET imaging, wherein
  • the isotopes are selected from the group consisting of 11C, 15O, and 18F;
  • the group of R1-R7 are selected as follows:
  • when R1 is a radiolabelled group incorporating or consisting of an isotope selected from 11C, 15O, and 18F, then R2-R7 is selected from H, F, methyl or methoxy;
  • when one or more of R2-R7 is a radiolabelled group incorporating or consisting of an isotope selected from the group consisting of 11C, 150, and 18F, then R1 is selected from H; C1-C6 alkyl such as methyl, ethyl, 1-propyl, 2-propyl, isobutyl; C1-C6 alkyl(C3-C8)cycloalkyl such as cyclopropylmethyl; C1-C6 hydroxyalkyl such as hydroxyethyl; flouropropyl; flouroethyl; and flourobutyl.
  • In a further aspect the invention relates to salts or hydrates of the compounds of present invention.
  • In a still further aspect the invention relates to methods of production and use of the compounds of the present invention.
    • BRIEF DESCRIPTION OF DRAWINGS
  • FIG. 1 shows PET SUV images, summation from 15 to 90 minutes after injection of [11C]Lu AE92686.
  • FIG. 2 shows PET SUV images, 15 to 90 minutes for two monkeys.
  • FIG. 3 shows kinetics of [11C]Lu AE92686 in striatum, results from two monkeys.
  • The X-axis indicates time (minutes), the Y-axis indicates SUV
  • FIG. 4 shows a dose response curve picturing [11C]Lu AE92686 binding to striatum after challenge with three doses of the selective PDE10A inhibitor PF2545920.
    •
  • The X-axis indicates mg/kg of PF2545920, the Y-axis indicates % occupancy.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention relates to radiolabelled compounds, their production and the use of said compounds for PET imaging.
    • Embodiments According to the Invention
  • In the following embodiments of the invention are disclosed. The first embodiment is denoted E1, the second embodiment is denoted E2 and so forth.
  • E1. A Compound according to Formula I
  • Figure US20130303770A1-20131114-C00002
  • comprising at least one isotope selected from the group consisting of 11C, 15O, and 18F, or a salt or a hydrate form of the compound.
  • E2. An embodiment according to Embodiment 1 where
      • R1 is a radiolabelled group comprising at least on isotope selected from the group consisting of 11C, 150, and 18F, and
      • R2-R7 are individually selected from H, F, methyl or methoxy.
  • E3. An embodiment according to Embodiment 1 where
      • one or more of R2-R7 is a radiolabelled group comprising an isotope selected from the group consisting of 11C, 15O, and 18F, or one or more of R2-R5 is 18F, and
      • R1 is selected from H; C1-C6 alkyl, such as methyl, ethyl, 1-propyl, 2-propyl, isobutyl; C1-C6 alkyl(C3-C8)cycloalkyl, such as cyclopropylmethyl; C1-C6 hydroxyalkyl, such as hydroxyethyl; flouropropyl; flouroethyl; and flourobutyl.
  • E4. The compound of El wherein R3, R4, and R5 are H and R7 is methyl.
  • E5. The compound of E2 and E4 wherein R2 is H and R6 is methyl.
  • E6. The compound according to E5 wherein R1 selected from the group consisting of 11CH3, —CH2 11CH3, —11CH2CH3, —CH2CH2 11CH3, —11CH2CH2CH3, —11CH2CH2CH2CH3, —CH2CH2CH2 11CH3, —CH2CH2 18F, —CH2CH2CH2 18F, —CH2CH2CH2CH2 18F.
  • E7. The compound according to E3 and E4 wherein R1 and R6 are methyl.
  • E8. The compound according to E7 wherein R2 is O11CH3 ([11C]methoxy).
  • E9. The compound according to E3 and E4 wherein R1 and R6 are methyl.
  • E10. The compound according to E9 wherein R2 is 18F.
  • E11. The compound according to E3 and E4 wherein R1 is CH3 and R2 is H.
  • E12. The compound according to E11 wherein R6 is O11CH3 ([11C]methoxy).
  • E13. The compound according to E1, wherein the compound is 5,8-Dimethyl-242-([11C-1-methyl]-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyridine.
  • E14. The compound according to E1, wherein the compound is 8-[11C]Methoxy-5-methyl-2-[2-(1-methyl-4-phenyl-1H-imidazol-2-yl)-ethyl]-(1,2,4]triazolo[1,5-a]pyridine).
  • E15. The compound according to E1, wherein the compound is 2-(2-[4-(2-[18F]Fluoro-phenyl)-1-methyl-1H-imidazol-2-yl]-ethyl}-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine.
  • E16. The compound according to E1, wherein the compound is 2-(2-∴2-[4-(2-[11C]Methoxy-phenyl)-1-methyl-1H-imidazol-2-yl]ethyl}-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine.
  • E17. Use of a compound according to any of E1-E16 as a PET ligand.
  • E18. The use according to E17 for determination of the binding occupancy of a PDE10A enzyme ligand at the PDE10A enzyme.
  • E19. A method for the preparation of a compound according to any of E1-E16.
  • Substituents
  • The term “C1-C6 alkyl” refers to a straight-chain or branched saturated hydrocarbon having from one to six carbon atoms, inclusive. Examples of such groups include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2-methyl-1-butyl, and n-hexyl. The expression “Cl -C6 hydroxyalkyl” refers to a C1-C6 alkyl group as defined above which is substituted with one hydroxy group.
  • The expression “C1-C6 alkoxy” refers to a straight-chain or branched saturated alkoxy group having from one to six carbon atoms, inclusive, with the open valency on the oxygen. Examples of such groups include, but are not limited to, methoxy, ethoxy, n-butoxy, 2-methyl-pentoxy and n-hexyloxy.
  • The term “C3-C8 cycloalkyl” typically refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl. The expression “C1-C6 alkyl(C3-C8)cycloalkyl” refers to a C3-C8 cycloalkyl as defined above which is substituted with a straight-chain or branched C1-C6 alkyl. Examples of such groups include, but are not limited to, cyclopropylmethyl.
  • Pharmaceutically Acceptable Salts
  • The present invention also comprises salts of the compounds, typically, pharmaceutically acceptable salts. Such salts include pharmaceutically acceptable acid addition salts. Acid addition salts include salts of inorganic acids as well as organic acids.
  • Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, sulfamic, nitric acids and the like. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, methanesulfonic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids, theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromotheophylline and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in Berge, S. M. et al., J. Pharm. Sci. 1977, 66, 2, the contents of which are hereby incorporated by reference.
  • Furthermore, the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.
  • Radiolabelled Compound
  • In the context of the present invention a radiolabelled compound is a compound comprising one or more isotopes selected from the group consisting of 11C, 15O, and 18F.
  • Radiolabelled Group
  • In the context of the present invention radiolabelled group is any of R1-R7 comprising at least one isotope selected from the group consisting of 11C, 18O, and 18F.
  • R1-R7 is short notation for the group consisting R1, R2, R3, R4, R5, R6, and R7.
  • Subsets of R1-R7 are defined similarly, e.g. R2-R6 means the group consisting R2, R3, R4, R5, and R6.
  • [11C]Lu AE92686
  • [11C]Lu AE92686 is the radiolabelled compound 5,8-dimethyl-2-[2-([11C-1-methyl]-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyridine
  • PF2545920
  • PF2545920 is the compound 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline as disclosed in J. Med. Chem., 2009, 52 (16), pp 5188-5196.
  • Standardized Uptake Value (SUV)
  • Standardized uptake value, SUV, which is a PET quantifier, calculated as a ratio of tissue radioactivity concentration (e.g. in units kBq/ml) at time T, CPET(T) and injected dose (e.g. in units MBq) at the time of injection divided by body weight (e.g. in units kg).
    • EXAMPLES Example 1 Preparation of the Compounds of the Invention
  • Scheme 1 represents a synthetic route towards compounds of formula I of the invention where R1 is a radiolabelled group. Unless otherwise indicated, in the reaction schemes and discussion that follow, R1-R7, are as defined above.
  • Figure US20130303770A1-20131114-C00003
  • Scheme 2 represents a synthetic route towards compounds of formula I of the invention where R6 is a radiolabelled group.
  • Figure US20130303770A1-20131114-C00004
  • Scheme 3 represents a synthetic route towards compounds of formula I of the invention where R2 is a radiolabelled group.
  • Figure US20130303770A1-20131114-C00005
  • One example of a synthetic route for the synthesis of the PET-preursor compound of formula IIa is shown in scheme 4: The (5,8-Dimethyl-[1,2,4]triazolo[1,5-a]pyridin-2-ylmethyl)-triphenyl-phosphonium salt 1 is coupled under basic conditions with commercially available 4-phenyl-1H-imidazole-2-carbaldehyde 2 (Anichem Inc. catalog number FH10994) to form the 5,8-Dimethyl-2-[2-(4-phenyl-1H-imidazol-2-yl)-vinyl]-[1,2,4]triazolo[1,5-a]pyridine, compound 3. The basic conditions are necessary in order to convert the phosphonium salt 1 into the corresponding Wittig-ylide compound 1A, which is the active nucleofile that condense with the aldehyde compound 2. Different bases can be used and DBU (1,8-Diazabicyclo[5.4.0]undec-7-ene) were found to give the best result. The product of the wittig reaction is the alkene compound 3, which is conveniently isolated in high yield and purity by precipitation from aqueous ethanol and can be used directly without further purification in the next step. The PET-preursor compound II is then formed from the alkene compound 3 by hydrogenation under a hydrogen atmosphere using a hydrogenation catalyst e.g. 5% palladium on charcoal.
  • Figure US20130303770A1-20131114-C00006
  • The syntheses of the starting material building block 1 is shortly described in the scheme 5, and the steps involved are: 1) To a solution of Ethyl O-mesitylsulfonylacetohydroxamate (43.50 g, 152.4 mmol) in 1,4-Dioxane (290 mL, 3700 mmol) cooled in an ice bath (freezes at 8-9° C.) was added 70% Perchloric acid (176.3 mL, 2.92 mol) dropwise over 15 minutes, maintaining internal temperature below 15° C. The mixture was then diluted with ice water (120 mL) to precipitate the product O-(mesitylsulfonyl)hydroxylamine which was filtered off, washed thoroughly with water, and immediately dissolved in (dichloromethane, DCM, 50 mL) while still wet. The organic layer was dried with MgSO4 and filtered.
  • 2) The obtained solution of O-(mesitylsulfonyl)hydroxylamine was added dropwise to a solution of commercially available 3,6-dimethyl-2-pyridinamine (16.4 g, 117 mmol) in DCM (100 mL) cooled in an ice bath. The mixture was then warmed to room temperature over 15 minutes. LCMS indicated almost complete conversion to the aminated intermediate.
  • 3) The solvent was evaporated and the residue was dissolved in Methanol (600 mL, 10000 mmol) followed by the addition of 1,8-Diazabicyclo[5.4.0]undec-7-ene (31.438 mL, 210.22 mmol). The solution was stirred at RT for 5 minutes where Chloroacetic acid methyl ester (10.3 mL, 117 mmol) was added and the solution stirred at room temperature, RT, for 48 hours. The volatiles were removed in vacuo. Water was added and the organics extracted with EtOAc. The combined organics were washed with water, brine, dried (MgSO4) filtered and the volatiles removed in vacuo. The residue was crystallised from heptane (400 mL), filtered and dried to yield 2-Chloromethyl-5,8-dimethyl-1,2,4]triazolo[1,5-a]pyridine (7.414 g; Yield=31.5%; Purity=97%).
  • Figure US20130303770A1-20131114-C00007
  • The syntheses of the PET-preursor compounds of formula Il-V is performed by methods analogues to those described in scheme 5. The starting materials and other reagents are available commercially or can be synthesized by well-known and conventional methods for example as described in WO 2009/152825.
    • Example 2 Synthesis of [11C] Lu AE92686: 5,8-Dimethyl-2-[2-([11C-1-methyl]-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyridine Production of [11C]CO2 and [11C]methyl iodide
  • A Scanditronix MC17 cyclotron was used to produce 11C via the 14N(p,alpha)11C nuclear reaction. The target was filled with a mixture of 0.05% oxygen in nitrogen and bombarded with 17 MeV protons to produce [11C]CO2. The labeled carbon dioxide was reduced with 0.2 M lithium aluminium hydride in tetrahydrofuran. Treatment with 56% aqueous hydroiodic acid gave [11C]methyl iodide which after drying with phosphorus pentoxide was used for the labeling of the precursor.
    • Synthesis of [11C]Lu AE92686
  • The precursor (2.5 mg) was dissolved in 300 microL of dry dimethylformamide and approximately 2 mg of crushed sodium hydroxide was added. After thorough shaking, the clear liquid was transferred to another vial. The labeled methyl iodide was introduced and the reaction mixture was heated at 70° C. for 90 seconds. Water (450 microL) was then added and the diluted reaction mixture was injected onto the preparative HPLC column. The collection vial for the product fraction contained 5 mg of ascorbic acid.
  • Isolation and Formulation
  • The solvent of the product fraction collected from the preparative chromatography was removed by means of a rotary evaporator and the residue was redissolved in 5 mL of sterile sodium chloride solution. When required for the biology experiments, the formulated tracer was filtered through a 0.2 micro m sterile filter.
  • The product was identified by analytical HPLC using co-injection of the non-radioactive reference compound by comparing the retention times of the UV and radioactive peaks. The total production time including formulation was about 30 minutes. A more rigorous identification of the tracer was done by LC/MS.
    • Example 3 Pharmacological Testing
  • PDE10A Enzyme
  • Active PDE10A enzyme is prepared in a number of ways for use in PDE assays (Loughney, K. et al. Gene 1999, 234, 109-117; Fujishige, K. et al. Eur J Biochem. 1999, 266, 1118-1127 and Soderling, S. et al. Proc. Natl. Acad. Sci. 1999, 96, 7071-7076). PDE10A can be expressed as full-length proteins or as truncated proteins, as long as they express the catalytic domain. PDE10A can be prepared in different cell types, for example insect cells or E. coli. An example of a method to obtain catalytically active PDE10A is as follows: The catalytic domain of human PDE10A (amino acids 440-779 from the sequence with accession number NP 006652) is amplified from total human brain total RNA by standard RT-PCR and is cloned into the BamH1 and Xho1 sites of the pET28a vector (Novagen). Expression in coli is performed according to standard protocols. Briefly, the expression plasmids are transformed into the BL21(DE3) E. coli strain, and 50 mL cultures inoculated with the cells allowed to grow to an OD600 of 0.4-0.6 before protein expression is induced with 0.5 mM IPTG. Following induction, the cells are incubated overnight at room temperature, after which the cells are collected by centrifugation. Cells expressing PDE10A are resuspended in 12 mL (50 mM TRIS-HCl-pH8.0, 1 mM MgCl2 and protease inhibitors). The cells are lysed by sonication, and after all cells are lysed, TritonX100 is added according to Novagen protocols. PDE10A is partially purified on Q sepharose and the most active fractions were pooled.
  • PDE10A inhibition Assay
  • A PDE10A inhibition assay may for example, be performed as follows: The assay is performed in 60 microL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide substrate), a buffer (50 mM HEPES7.6; 10 mM MgCl2; 0.02% Tween20), 0.1mg/mL BSA, 225 pCi of 3H-labelled cyclic nucleotide substrate, tritium labeled cAMP to a final concentration of 5 nM and varying amounts of inhibitors. Reactions are initiated by addition of the cyclic nucleotide substrate, and reactions are allowed to proceed for one hour at room temperature before being terminated through mixing with 15 uL 8 mg/mL yttrium silicate SPA beads (Amersham). The beads are allowed to settle for one hour in the dark before the plates are counted in a Wallac 1450 Microbeta counter. The measured signal can be converted to activity relative to an uninhibited control (100%) and IC50 values can be calculated using the Xlfit extension to EXCEL.
  • In the context of the present invention the assay was performed in 60 micro L assay buffer (50 mM HEPES pH 7.6; 10 mM MgCl2; 0.02% Tween20) containing enough PDE10A to convert 20-25% of 10 nM 3H-cAMP and varying amounts of inhibitors. Following one hour incubation the reactions were terminated by addition of 15 microL 8 mg/mL yttrium silicate SPA beads (Amersham). The beads were allowed to settle for one hour in the dark before the plates were counted in a Wallac 1450 Microbeta counter. IC50 values were calculated by non linear regression using XLfit (IDBS).
  • Results of the PDE10A inhibition assay showed that Lu AE92686 has a very high affinity for the PDE10A enzyme an IC50 value of 0.46 nM. Furthermore, Lu AE92686 is selective for the PDE10A enzyme over other receptors and enzymes screened to date (table 1).
  • TABLE 1
    Inhibition Inhibition
    @10 μM @10 μM
    Assay (%) Assay (%)
    A1 (h) (antagonist radioligand) 2 M5 (h) (antagonist radioligand) 17
    A1 (h) (agonist radioligand) 4 NK1 (h) (agonist radioligand) 29
    A2A (h) (agonist radioligand) 24 NK2 (h) (agonist radioligand) 31
    A3 (h) (agonist radioligand) 32 Y1 (h) (agonist radioligand) 9
    alpha 1A (h) (antagonist radioligand) 33 N neuronal alpha-BGTX-insensitive (alpha 12
    4beta 2) (agonist radioligand)
    alpha 1B (h) (antagonist radioligand) 26 N muscle-type (h) (antagonist radioligand) 0
    alpha 1D (h) (antagonist radioligand) 16 delta 2 (DOP) (h) (agonist radioligand) 25
    alpha 2A (h) (antagonist radioligand) 13 kappa (KOP) (agonist radioligand) 62
    alpha 2B (h) (antagonist radioligand) 33 mu (MOP) (h) (agonist radioligand) 41
    beta 1 (h) (agonist radioligand) −4 PCP (antagonist radioligand) −2
    beta 2 (h) (agonist radioligand) −6 rolipram (antagonist radioligand) 31
    BZD (central) (agonist radioligand) 3 5-HT1A (h) (agonist radioligand) 89
    CB1 (h) (agonist radioligand) 0 5-HT1B (antagonist radioligand) 18
    CCK2 (CCKB) (h) (agonist radioligand) 23 5-HT2A (h) (agonist radioligand) 3
    D1 (h) (antagonist radioligand) −3 5-HT2B (h) (agonist radioligand) 23
    D2S (h) (antagonist radioligand) 7 5-HT2C (h) (agonist radioligand) 32
    D2S (h) (agonist radioligand) 18 5-HT3 (h) (antagonist radioligand) 1
    D3 (h) (antagonist radioligand) 4 5-HT4e (h) (antagonist radioligand) 24
    D4.4 (h) (antagonist radioligand) 47 5-HT7 (h) (agonist radioligand) 15
    ETA (h) (agonist radioligand) −3 sigma (non-selective) (agonist radioligand) 8
    GABAA (agonist radioligand) −18 GR (h) (agonist radioligand) 0
    H1 (h) (antagonist radioligand) −5 UT (h) (agonist radioligand) 9
    H2 (h) (antagonist radioligand) 24 Ca2+ channel (L, dihydropyridine site) (antagonist 15
    radioligand)
    H3 (h) (agonist radioligand) 1 Ca2+ channel (L, diltiazem site) (benzothiazepines) 25
    (antagonist radioligand)
    MC4 (h) (agonist radioligand) 3 Ca2+ channel (L, verapamil site) (phenylalkylamine) 4
    (antagonist radioligand)
    MT1 (ML1A) (h) (agonist radioligand) 45 Ca2+ channel (N) (antagonist radioligand) −8
    MT3 (ML2) (agonist radioligand) 94 Na+ channel (site 2) (antagonist radioligand) 36
    MAO-A (antagonist radioligand) 2 norepinephrine transporter (h) (antagonist 4
    radioligand)
    M1 (h) (antagonist radioligand) −4 dopamine transporter (h) (antagonist radioligand) 7
    M2 (h) (antagonist radioligand) 20 GABA transporter (antagonist radioligand) −13
    M3 (h) (antagonist radioligand) 4 choline transporter (CHT1) (h) (antagonist 12
    radioligand)
    M4 (h) (antagonist radioligand) 18 5-HT transporter (h) (antagonist radioligand) 6
    • Example 4 PDE10A Enzyme Localization in the Brain
  • Preparation
  • The monkey is sedated with ketamin (approximately 10 mg/kg), weighed, and maintained on a constant infusion of ketamin 15 mg/kg/h during transport. During transport the monkey is monitored by pulse oximetry and supported by oxygen. One venous catheter is applied for tracer administration and one venous catheter for blood radioactivity and PK sampling. Propofol is administered until the animal is anesthetized enough to intubate. After intubation the animal is maintained on sevoflurane inhalation anesthesia and artificial ventilation.
  • Blood Sampling
  • A 115 microL venous sample is taken at the induction of anesthesia and at the middle and end of experiment for estimation of electrolytes, glucose, hematocrite and glucose.
  • Blood samples (0.2 mL for radioactivity determination are taken at 0.5, 1, 3, 5, 10, 15, 20, 30, 45, 60 and 90 minutes after injection. The samples are labeled with time, date, sampling time in relation to injection, and project number.
  • Blood samples (2 mL) for metabolite analysis are obtained at 5, 30, and 90 minutes after injection of the tracer.
  • Blood sample (1.3 mL) for assessment of free tracer fraction in plasma is taken shortly before each tracer injection.
  • For PK analysis of the study drug, 0.5 mL blood samples are collected 1 minute after the end of each infusion and at 0.5, 15, 30, 60 and 90 minutes after injection of the radiolabelled compound. The samples are collected in tubes containing K3EDTA (Microvette 500 K3E, Sarstedt), which are inversed several times to ensure mixing of anticoagulant and blood and stored on ice. The blood samples are centrifuged within 30 minutes and plasma is transferred to a clean polypropylene tube. The samples are stored at −80° C.
  • Total amount of blood taken: less than 35 mL (chosen monkey weighs approximately 5 kg)
  • Anaesthesia: The monkey is intubated and controlled by respirator at a sevoflurane concentration of about 1.4-4%.
  • Infusion: Ringer-Acetate (Fresenius-Kabi) 0.5-1 ml/kg/h.
  • Monitoring
  • Body temperature, heart rate, ECG, pCO2, pO2, SaO2 and blood pressure are monitored throughout the PET study.
  • Awakening
  • 1 mL robinyl/neostigmin 2.5 mg is administered when the monkey shows signs of spontaneous breathing. Glucose 300 mg/ml is administered if necessary depending on the blood glucose state as measured.
  • 11C-PET-Studies
  • A bolus injection (i.v.) of approximately 5-20 MBq/kg of [11C]Lu AE92686 is used in all studies. PET scanning and arterial blood sampling is commenced upon start of the administration of the radiolabelled compound.
  • PET: Emission Protocol
  • Frame Number Accumulated time (minutes)
    12 frames à 10 seconds  1-12 2
    6 frames à 30 seconds 13-18 5
    5 frames à 2 minutes 19-23 15
    5 frames à 5 minutes 24-28 40
    5 frames à 10 minutes 29-33 90
  • Total examination time: 90 minutes, 33 frames.
  • Reconstruction: filter Hann 4, 128 matrix.
  • Analysis of PET Data
  • The results show, that [11 C]Lu AE92686 readily enters the brain reaching peak regional tissue concentrations at approximately 10-15 minutes post injection followed by washout from brain regions known to be rich in PDE10A with highest uptake and retention observed in striatum (FIG. 1 and FIG. 3): [11C]Lu AE92686 concentration was low in cerebellum (FIG. 1), a brain region known to possess very low level of PDE10A.
    • Example 5 Saturation of PDE10A Enzyme in the Brain
  • The selective PDE10A inhibitor PF2545920 (J. Med. Chem., 2009, 52 (16), pp 5188-5196) was administered intravenously, as an infusion over 15 minutes, starting 30 minutes prior to injection of the [11C]Lu AE92686 radiolabelled compound. PF2545920 was dissolved in 10% HPbetaCD in 0.9% NaCl, pH 4. Three blocking doses of PF2545920 were administered, at concentrations of the drug of 0.11 mg/kg (for the low dose), 0.6 mg/kg (for the middle dose) and 1.5 mg/kg (for the high dose).
  • The per cent occupancy of PDE10A as a function of concentration of blocking substance was measured (FIG. 1 and FIG. 2) as well as the inter-individual variability of the brain kinetics of [11C]Lu AE92686 (FIG. 2). Cerebellum has been identified as the reference tissue due to its low content of PDE10A. Based on these measurements a dosis-response curve was drawn (FIG. 4) showing the correlation between dose of PDE10 inhibitor PF2545920 and the occupancy of striatal PDE10A.
  • The Kinetics of the PET ligand [11 C]Lu AE92686 in striatum was also measured at different doses in two different monkeys (FIG. 3)

Claims (19)

1. A compound according to Formula I
Figure US20130303770A1-20131114-C00008
comprising at least one isotope selected from the group consisting of 11C, 15O, and 18F, wherein
R1 is a radiolabelled group comprising at least one isotope selected from the group consisting of 11C, 15O, and 18F; and
R2-R7 are each individually selected from H, fluoro, methyl or methoxy;
or a salt or a hydrate form of the compound.
2. The compound of claim 1 wherein R3, R4, and R5 are H and R7 is CH3.
3. The compound of claim 2 wherein R2 is H and R6 is CH3.
4. The compound according to claim 3 wherein R1 is selected from the group consisting of 11CH3; —CH2 11CH3; —11CH2CH3; —CH2CH2 11CH3; —11CH2CH2CH3; —11CH2CH2CH3; —CH2CH2CH2 11CH3; —CH2CH2 18F; —CH2CH2CH2 18F; and —CH2CH2CH2CH2 18F.
5. The compound according to claim 4 wherein R1 is 11CH3 [11C]methyl).
6-11. (canceled)
12. The compound according to claim 1, wherein the compound is selected from the group consisting of
5,8-dimethyl-2-[2-([11C-1-methyl]-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo-[1,5-a]pyridine;
2-{2-[4-(2-[11C]methoxy-phenyl)-1-methyl-1H-imidazol-2-yl}-ethyl}-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine; and
2-{2-[4-(2-[18F]fluoro-phenyl)-1-methyl-1H-imidazol-2-yl]-ethyl}-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine.
13-15. (canceled)
16. A compound according to Formula I
Figure US20130303770A1-20131114-C00009
comprising at least one isotope selected from the group consisting of 11C, 15O, and 18F; wherein
when one or more of R2-R7 is a radiolabelled group comprising an isotope selected from the group consisting of 11C, 15O, and 18P, or
when one or more of R2-R5 is 18F;
then R1 is selected from the group consisting of H; C1-C6 alkyl; C1-C-6alkyl(C3-C8)cycloalkyl; C1-C6 hydroxyalkyl; flouropropyl; flouromethyl; and flourobutyl;
or a salt or a hydrate form of the compound,
17. The compound of claim 16 wherein R3, R4, and R5 are H and R7 is CH3.
18. The compound of claim 17 wherein R1 and R6 are CH3.
19. The compound of claim 18 wherein R2 is C11CH3([11C]methoxy).
20. The compound of claim 17 wherein R1 and R6 are CH3.
21. The compound of claim 20 wherein R2 is 18F.
22. The compound of claim 2 wherein R1 is CH3 and R2 is H.
23. The compound of claim 22 wherein R6 is O11CH3([11C]methoxy).
24. The compound of claim 16 wherein R1 is methyl, ethyl, 1-propyl, 2-propyl, or isobutyl.
25. The compound of claim 16 wherein R1 is cyclopropylmethyl or hydroxyethyl.
26. The compound of claim 12, wherein the compound is 5,8-dimethyl-2-[2-([11C-1-methyl]-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyridine.
US13/890,705 2010-11-10 2011-11-10 Radiolabelled phenylimidazole-based ligands Expired - Fee Related US8592449B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/890,705 US8592449B1 (en) 2010-11-10 2011-11-10 Radiolabelled phenylimidazole-based ligands

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41193410P 2010-11-10 2010-11-10
DKPA201001023 2010-11-10
DKPA201001023 2010-11-10
DK201001023 2010-11-10
PCT/DK2011/000132 WO2012062319A1 (en) 2010-11-10 2011-11-10 Radiolabelled phenylimidazole-based ligands
US13/890,705 US8592449B1 (en) 2010-11-10 2011-11-10 Radiolabelled phenylimidazole-based ligands

Publications (2)

Publication Number Publication Date
US20130303770A1 true US20130303770A1 (en) 2013-11-14
US8592449B1 US8592449B1 (en) 2013-11-26

Family

ID=45098760

Family Applications (1)

Application Number Title Priority Date Filing Date
US13/890,705 Expired - Fee Related US8592449B1 (en) 2010-11-10 2011-11-10 Radiolabelled phenylimidazole-based ligands

Country Status (18)

Country Link
US (1) US8592449B1 (en)
EP (1) EP2637704B9 (en)
JP (1) JP5820887B2 (en)
CN (1) CN103732260B (en)
AU (1) AU2011328598B2 (en)
CA (1) CA2817385A1 (en)
DK (1) DK2637704T5 (en)
ES (1) ES2539464T3 (en)
HR (1) HRP20150560T2 (en)
HU (1) HUE025511T2 (en)
ME (1) ME02145B (en)
PL (1) PL2637704T4 (en)
PT (1) PT2637704E (en)
RS (1) RS54039B1 (en)
SG (1) SG190686A1 (en)
SI (1) SI2637704T1 (en)
SM (1) SMT201500139B (en)
WO (1) WO2012062319A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9790203B2 (en) 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
BR112015016995B8 (en) * 2013-01-15 2022-07-26 Novartis Ag USE OF ACETYLCHOLINE ALPHA 7 NICOTINE RECEPTOR AGONISTS
KR20150111354A (en) * 2013-01-31 2015-10-05 에프. 호프만-라 로슈 아게 Radiolabeled compounds
BR112020013820A2 (en) 2018-11-06 2021-06-01 H. Lundbeck A/S pde10a inhibitors to treat negative symptoms and cognitive impairment in a patient suffering from schizophrenia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0425548D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd Radiolabelled ligands
EP1836164B1 (en) 2005-01-13 2011-08-24 GE Healthcare Limited 11c-labeled benzyl-lactam compounds and their use as imaging agents
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
EP2036578A1 (en) 2007-09-13 2009-03-18 Bayer Schering Pharma Aktiengesellschaft Diagnostic agents for positron emission imaging using F-18 radio labeled amino-alcohols
TWI501965B (en) 2008-06-20 2015-10-01 Lundbeck & Co As H Novel phenylimidazole derivatives as pde10a enzyme inhibitors
US20110305637A1 (en) 2009-02-24 2011-12-15 Janssen Pharmaceutica N.V. Radiolabelled pde10 ligands

Also Published As

Publication number Publication date
DK2637704T5 (en) 2015-09-21
SI2637704T1 (en) 2015-07-31
HRP20150560T2 (en) 2015-11-20
JP2013543851A (en) 2013-12-09
CA2817385A1 (en) 2012-05-18
CN103732260B (en) 2018-08-10
AU2011328598B2 (en) 2016-04-21
PL2637704T3 (en) 2015-08-31
US8592449B1 (en) 2013-11-26
DK2637704T3 (en) 2015-06-22
ME02145B (en) 2015-10-20
EP2637704B1 (en) 2015-03-25
PT2637704E (en) 2015-07-21
HUE025511T2 (en) 2016-04-28
WO2012062319A1 (en) 2012-05-18
HK1189498A1 (en) 2014-06-13
SG190686A1 (en) 2013-07-31
AU2011328598A1 (en) 2013-05-30
SMT201500139B (en) 2015-09-07
EP2637704B9 (en) 2015-08-05
PL2637704T4 (en) 2015-08-31
EP2637704A1 (en) 2013-09-18
CN103732260A (en) 2014-04-16
JP5820887B2 (en) 2015-11-24
RS54039B1 (en) 2015-10-30
ES2539464T3 (en) 2015-07-01
HRP20150560T1 (en) 2015-07-03

Similar Documents

Publication Publication Date Title
US8530483B2 (en) Substituted azabenzoxazoles
JP2016056184A (en) Phosphodiesterase 1-target tracer and method
US8592449B1 (en) Radiolabelled phenylimidazole-based ligands
TW200804363A (en) Novel radioligands
US20110076230A1 (en) Novel Substituted Indoles
US20110212031A1 (en) Novel substituted azabenzoxazoles
US10865195B2 (en) Pet imaging agents
US20240343737A1 (en) Imaging Agents
WO2025094152A1 (en) 18f and11c radiolabeled mchr1 pet ligands
HK1189498B (en) Radiolabelled phenylimidazole-based ligands
US20160031878A1 (en) Radiolabeled compounds
US9610369B2 (en) Compound suitable for detection of vesicular acetylcholine transporter
EA040922B1 (en) VISUALIZING TOOLS

Legal Events

Date Code Title Description
AS Assignment

Owner name: H. LUNDBECK A/S, DENMARK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KEHLER, JAN;BANG-ANDERSEN, BENNY;SIGNING DATES FROM 20130729 TO 20130730;REEL/FRAME:030911/0514

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20211126